Treats HER2-positive metastatic breast cancer (MBC). Sold as Perjeta. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Pertuzumab (sold as Perjeta), first approved Jun 8, 2012, with 7 new uses approved and 0 published complete response letters.
| Perjeta | Part B | $289M | -3% | 5,323 |
| Perjeta | Part D | $13.8M | +33% | 298 |
| Neoadjuvant Trastuzumab, Pertuzumab and Zongertinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-5 StudyHER2-positive Breast Cancer, Early Breast Cancer (EBC) · The Netherlands Cancer Institute | Phase 1 | Not yet recruiting | Nov 10, 2026 |
| Comparative Study of QL1209 and Perjeta® in Healthy Male ParticipantsBreast Cancer · Qilu Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Oct 6, 2026 |
| Trastuzumab/Pertuzumab With Fulvestrant and Culmerciclib in HR+/HER2+ Early Breast CancerBreast Cancer · Hebei Medical University Fourth Hospital | Phase 2 | Not yet recruiting | Oct 5, 2026 |
| SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete ResponseHER2-positive Breast Cancer, Early Breast Cancer (EBC) · Fudan University | Phase 2 | Not yet recruiting | Oct 2, 2026 |
| Clinical and Therapeutic Outcomes by Molecular Subtype in Breast CancerBreast Neoplasms, Triple Negative Breast Neoplasms · Fundación Santa Fe de Bogota | — | Recruiting | Oct 2, 2026 |
| HER2-positive Breast Cancer Without Intravenous Neoadjuvant TherapyHER 2 Positive Advanced Breast Cancer · The First Affiliated Hospital with Nanjing Medical University | Phase 2 | Not yet recruiting | Sep 30, 2026 |
| Pyrotinib for HER2-Positive Advanced Breast Cancer Previously Treated With Trastuzumab and PertuzumabBreast Cancer · Beijing 302 Hospital | — | Active, not recruiting | Sep 9, 2026 |
| Molecularly Tailored Therapy in Advanced Pancreatic CancerPancreatic Cancer · Herlev Hospital | Phase 2 | Not yet recruiting | Sep 3, 2026 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA